Get the Stockscreener App
1.03
1.90%
-0.02
Pre-market:
1.03
Mira Pharmaceuticals Inc stock is traded at $1.03, with a volume of 46,691.
It is down -1.90% in the last 24 hours and down -14.88% over the past month.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.
See More
Previous Close:
$1.05
Open:
$1.04
24h Volume:
46,691
Relative Volume:
0.30
Market Cap:
$43.28M
Revenue:
-
Net Income/Loss:
$-32.00M
P/E Ratio:
-0.6786
EPS:
-1.5178
Net Cash Flow:
$-4.66M
1W Performance:
-0.96%
1M Performance:
-14.88%
6M Performance:
-21.97%
1Y Performance:
+14.80%
1-Day Range:
$1.03
$1.0597
1-Week Range:
$0.9902
$1.07
52-Week Range:
$0.83
$2.45
Mira Pharmaceuticals Inc Stock (MIRA) Company Profile
Name
Mira Pharmaceuticals Inc
Sector
Industry
Phone
813-369-5150
Address
1200 BRICKELL AVENUE, MIAMI
Compare MIRA vs LLY, JNJ, ABBV, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIRA
Mira Pharmaceuticals Inc
|
1.03 | 44.12M | 0 | -32.00M | -4.66M | -1.5178 |
LLY
Lilly Eli Co
|
905.03 | 824.12B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
238.67 | 578.31B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
208.42 | 371.90B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
201.21 | 316.96B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
117.90 | 296.29B | 64.93B | 18.26B | 12.36B | 7.2751 |
Mira Pharmaceuticals Inc Stock (MIRA) Latest News
Aug Summary: How does MIRA Pharmaceuticals Inc compare to its peersWeekly Investment Recap & AI Driven Stock Movement Reports - baoquankhu1.vn
MIRA Pharmaceuticals, Inc.: Fundamental Analysis and Financial Ratings | K6S | US60458C1045 - marketscreener.com
MIRA Pharmaceuticals : Investor Presentation - marketscreener.com
MIRA Technical Analysis & Stock Price Forecast - Intellectia AI
MIRA completes Phase 1 trial of oral NMDA drug Ketamir-2 - Investing.com
MIRA Pharmaceuticals Inc. (MIRA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Investment Report: How does MIRA Pharmaceuticals Inc compare to its peersPortfolio Gains Report & Weekly High Return Stock Opportunities - baoquankhu1.vn
Mira Pharmaceuticals Inc (K6S.MU) stock price, news, quote and history - Yahoo Finance UK
MIRA Pharmaceuticals (MIRA) CEO granted 83,500 RSUs - Stock Titan
MIRA Should I Buy - Intellectia AI
Cash strain and trial progress at MIRA Pharmaceuticals (NASDAQ: MIRA) - Stock Titan
Mira Pharmaceuticals 10-K: $— Revenue, $(1.35) EPS, $(10.44)M Net Loss - tradingview.com
MIRA Pharmaceuticals | 10-K: FY2025 Annual Report - Moomoo
MIRA Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
MIRA Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
What's going on with MIRA Pharma stock Tuesday? - MSN
Institution Moves: Can MIRA Pharmaceuticals Inc deliver alphaWeekly Gains Summary & Daily Volume Surge Trade Alerts - baoquankhu1.vn
Analyst Downgrade: What are MIRA Pharmaceuticals Incs recent SEC filings showing2026 WrapUp & Community Shared Stock Ideas - baoquankhu1.vn
Retail Surge: Is MIRA Pharmaceuticals Inc a strong growth stockMarket Growth Report & Weekly Setup with High ROI Potential - baoquankhu1.vn
MIRA Pharmaceuticals, Inc.Common Stock (NQ:MIRA) - FinancialContent
What's Going On With MIRA Pharma Stock Tuesday? - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
MIRA’s Mira-55 shows no CNS side effects in preclinical tests By Investing.com - Investing.com India
MIRA Pharmaceuticals Highlights Encouraging Safety Data for Mira-55 - TipRanks
MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies - The Desert Sun
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Mira Pharmaceuticals, Inc. Announces Positive Preclinical Results for Mira-55, a Non-Opioid Pain and Anxiety Treatment - Minichart
Mira Pharmaceuticals reports preclinical results for Mira-55 with no observed THC- or rimonabant-like CNS side effects - Investing.com India
MIRA’s Mira-55 shows no CNS side effects in preclinical tests - investing.com
MIRA Pharmaceuticals (MIRA) posts Mira-55 CNS and pain preclinical data - Stock Titan
MIRA pain drug showed morphine-like relief without THC-like effects - Stock Titan
Aug EndMonth: What is the Moat Score of MIRA Pharmaceuticals Inc2026 Macro Moves & Weekly Return Optimization Plans - baoquankhu1.vn
Momentum Shift: Can MIRA Pharmaceuticals Inc maintain its current growth rateRate Cut & Precise Swing Trade Alerts - baoquankhu1.vn
Macro Review: Can MIRA Pharmaceuticals Inc maintain its current growth rateTrade Ideas & Reliable Price Breakout Signals - baoquankhu1.vn
Dividend Watch: Can MIRA Pharmaceuticals Inc deliver alphaQuarterly Profit Report & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Short Interest in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Drops By 13.9% - MarketBeat
Aug Ideas: What is the Moat Score of MIRA Pharmaceuticals IncTrade Exit Summary & Entry Point Confirmation Signals - baoquankhu1.vn
MIRA Pharmaceuticals completes dosing in Ketamir-2 Phase I trial - MSN
Wall Street Recap: What are MIRA Pharmaceuticals Incs recent SEC filings showing2025 Historical Comparison & Weekly High Return Stock Forecasts - baoquankhu1.vn
Winners Losers: Can MIRA Pharmaceuticals Inc deliver alphaQuarterly Risk Review & Step-by-Step Trade Execution Guides - baoquankhu1.vn
MIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2 - ACCESS Newswire
MIRA tests oral Ketamir-2 for chemo nerve pain after safe Phase 1 - Stock Titan
MIRA Pharmaceuticals, Inc. (MIRA) Competitors - Meyka
MIRA Completes Phase 1 Trial of Ketamir-2 Therapy - TipRanks
Mira Pharmaceuticals Inc completes phase 1 dosing of Ketamir-2SEC filing - marketscreener.com
Mira Pharmaceuticals IncCompletes Phase 1 Dosing Of Ketamir-2SEC Filing - TradingView
MIRA Pharmaceuticals (NASDAQ: MIRA) finishes Ketamir-2 Phase 1 dosing with encouraging safety - Stock Titan
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Up 29.4% in February - MarketBeat
Ideas Watch: How does MIRA Pharmaceuticals Inc compare to its peersPortfolio Risk Summary & Verified Momentum Stock Watchlist - baoquankhu1.vn
Risk Analysis: What is the Moat Score of MIRA Pharmaceuticals IncWeekly Earnings Recap & Real-Time Price Movement Reports - baoquankhu1.vn
Mira Pharmaceuticals Inc Stock (MIRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.30%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):